Why the study?
Does intrarenal administration of doxorubicin-loaded albumin microspheres alter pharmacokinetics and reduce systemic exposure compared to doxorubicin solution?
Does intrarenal administration of doxorubicin-loaded albumin microspheres alter pharmacokinetics and reduce systemic exposure compared to doxorubicin solution?
Chemoembolization with doxorubicin-loaded microspheres significantly reduces systemic exposure while maintaining intrarenal drug levels compared to standard solution.
May reduce systemic doxorubicin exposure in renal chemoembolization; leaves open translation to human efficacy and safety.
We synthesized doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH)-loaded human albumin microspheres (containing approximately 1% doxorubicin w/w) between 15 and 20 micron in diameter. Intrarenal arterial administration of 99mTC-labeled microspheres demonstrated a high renal entrapment ratio (97% of recovered radioactivity). The pharmacokinetics and metabolism of doxorubicin are different when it is administered in microspherical form. Peak plasma levels are lower (16 ng/ml versus 135 ng/ml) compared with treatment by a doxorubicin solution. Histologic studies showed that the microspheres were trapped within capillaries and small arterioles in the renal vascular arcade. It is apparent that chemoembolization with doxorubicin-loaded microspheres significantly reduces systemic exposure to the antineoplastic agent, and maintains intrarenal drug levels.
No takes yet. Share an insight, caveat, or question.
Kerr et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: